November 1, 2018 / 3:03 PM / 17 days ago

BRIEF-Novartis Gets Health Canada Approval For Tafinlar/Mekinist Combination

Nov 1 (Reuters) - Novartis AG:

* NOVARTIS RECEIVES HEALTH CANADA APPROVAL FOR THE COMBINATION THERAPY OF TAFINLAR® (DABRAFENIB) PLUS MEKINIST® (TRAMETINIB) FOR ADJUVANT TREATMENT OF PATIENTS WITH BRAF V600 MUTATION MELANOMA(I)

* NOVARTIS PHARMACEUTICALS CANADA SAYS APPROVAL OF TAFINLAR PLUS MEKINIST COMBINATION IS BASED ON RESULTS FROM THE PHASE III COMBI-AD GLOBAL STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below